Larimar Therapeutics (LRMR) Stock Forecast, Price Target & Predictions
LRMR Stock Forecast
Larimar Therapeutics stock forecast is as follows: an average price target of $14.50 (represents a 101.39% upside from LRMR’s last price of $7.20) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LRMR Price Target
The average price target for Larimar Therapeutics (LRMR) is $14.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $4.00. This represents a potential 101.39% upside from LRMR's last price of $7.20.
LRMR Analyst Ratings
According to 2 Wall Street analysts, Larimar Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LRMR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Larimar Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Joori Park | Leerink Partners | $25.00 | $7.57 | 230.25% | 247.22% |
| Dec 13, 2022 | - | Citigroup | $4.00 | $3.97 | 0.76% | -44.44% |
The latest Larimar Therapeutics stock forecast, released on Apr 03, 2024 by Joori Park from Leerink Partners, set a price target of $25.00, which represents a 230.25% increase from the stock price at the time of the forecast ($7.57), and a 247.22% increase from LRMR last price ($7.20).
Larimar Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $25.00 |
| Last Closing Price | $7.20 | $7.20 | $7.20 |
| Upside/Downside | -100.00% | -100.00% | 247.22% |
In the current month, the average price target of Larimar Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Larimar Therapeutics's last price of $7.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 22, 2024 | Citigroup | Buy | Buy | Hold |
| May 21, 2024 | William Blair | Outperform | Outperform | Hold |
| May 21, 2024 | William Blair | Hold | Hold | Hold |
| Dec 13, 2022 | Citigroup | - | Neutral | Initialise |
| Sep 19, 2022 | William Blair | - | Outperform | Upgrade |
Larimar Therapeutics's last stock rating was published by Citigroup on May 22, 2024. The company gave LRMR a "Buy" rating, the same as its previous rate.
Larimar Therapeutics Financial Forecast
Larimar Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Larimar Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LRMR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Larimar Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict LRMR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Larimar Therapeutics's previous annual EBITDA (undefined) of $NaN.
Larimar Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-51.45M | $-49.17M | $-46.88M | $-42.68M | $-39.56M | $-36.53M | $-33.81M | $-30.62M | $-26.40M | $-23.95M | $-19.48M |
| High Forecast | $-51.45M | $-49.17M | $-46.88M | $-42.68M | $-39.56M | $-36.53M | $-33.81M | $-30.62M | $-26.40M | $-18.77M | $-19.48M |
| Low Forecast | $-51.45M | $-49.17M | $-46.88M | $-42.68M | $-39.56M | $-36.53M | $-33.81M | $-30.62M | $-26.40M | $-27.19M | $-19.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Larimar Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LRMR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Larimar Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Larimar Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LRMR last annual SG&A of $NaN (undefined).
Larimar Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.81 | $-0.77 | $-0.73 | $-0.67 | $-0.62 | $-0.57 | $-0.53 | $-0.48 | $-0.41 | $-0.38 | $-0.31 |
| High Forecast | $-0.81 | $-0.77 | $-0.73 | $-0.67 | $-0.62 | $-0.57 | $-0.53 | $-0.48 | $-0.41 | $-0.29 | $-0.31 |
| Low Forecast | $-0.81 | $-0.77 | $-0.73 | $-0.67 | $-0.62 | $-0.57 | $-0.53 | $-0.48 | $-0.41 | $-0.43 | $-0.31 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Larimar Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LRMR previous annual EPS of $NaN (undefined).
Larimar Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| IMRX | Immuneering | $2.02 | $17.50 | 766.34% | Buy |
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CHRS | Coherus BioSciences | $1.30 | $9.00 | 592.31% | Hold |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.99 | $19.50 | 14.77% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
LRMR Forecast FAQ
Is Larimar Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Larimar Therapeutics (LRMR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of LRMR's total ratings.
What is LRMR's price target?
Larimar Therapeutics (LRMR) average price target is $14.5 with a range of $4 to $25, implying a 101.39% from its last price of $7.2. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Larimar Therapeutics stock go up soon?
According to Wall Street analysts' prediction for LRMR stock, the company can go up by 101.39% (from the last price of $7.2 to the average price target of $14.5), up by 247.22% based on the highest stock price target, and down by -44.44% based on the lowest stock price target.
Can Larimar Therapeutics stock reach $11?
LRMR's average twelve months analyst stock price target of $14.5 supports the claim that Larimar Therapeutics can reach $11 in the near future.
What are Larimar Therapeutics's analysts' financial forecasts?
Larimar Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-141M, low $-141M), average SG&A $0 (high $0, low $0), and average EPS is $-2.202 (high $-2.202, low $-2.202). LRMR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-190M (high $-190M, low $-190M), average SG&A $0 (high $0, low $0), and average EPS is $-2.981 (high $-2.981, low $-2.981).